

## **ASX ANNOUNCEMENT**

**4 June 2024**

### **Notice under section 708AA(2)(f) of the Corporations Act 2001 (Cth)**

---

This notice is given by IDT Australia Limited (ASX: IDT) (**Company**) under section 708AA(2)(f) of the *Corporations Act 2001* (Cth) (as modified by ASIC Corporations (Non-Traditional Rights Issues) Instrument 2016/84) (the **Act**).

IDT has today announced that it intends to raise approximately \$7 million (before costs) by undertaking a fully underwritten non-renounceable entitlement offer of fully paid ordinary shares to existing eligible shareholders (**Entitlement Offer**).

The Entitlement Offer consists of an offer of 1 new fully paid ordinary share (**New Shares**) for every 4.5 shares held by eligible IDT shareholders as at 7.00 pm (Melbourne time) on 7 June 2024 (**Eligible Shareholders**) at an issue price of \$0.09 per New Share.

For the purposes of section 708AA(7) of the Act, the Company hereby notifies ASX that:

- (a) the New Shares will be offered for issue without disclosure to Eligible Shareholders under Part 6D.2 of the Act;
- (b) this notice is given under section 708AA(2)(f) of the Act;
- (c) as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Act;
- (d) as at the date of this notice, there is no other information that is 'excluded information' of the type referred to in sections 708AA(8) and 708AA(9) of the Act, which is required to be disclosed pursuant to section 708AA(7)(d) of the Act; and
- (e) the potential effect of the Entitlement Offer on the control of the Company, and the consequences of that effect, will depend on a number of factors, including existing shareholdings, investor demand and the existing shareholder participation in the Entitlement Offer. However, having regard to the structure of the Entitlement Offer being structured as a fully underwritten pro-rata issue, and the current level of holdings of substantial holders (based on the substantial holding notices that have been provided to the Company and lodged with ASX on, or before, the date of this notice), the Company does not currently expect the issue of New Shares under the Entitlement Offer to have a material effect on the control of the Company.

**End**

Authorised by the Board of Directors of IDT Australia Limited.

**About IDT**

IDT (ASX:IDT) is an Australian pharmaceutical manufacturing company based in Boronia, Victoria, Australia. The Company has extensive experience in the development and production of high potency and high containment pharmaceutical products for local and international clients. IDT's facilities are cGMP compliant and are regularly audited by the US FDA and Australian TGA. With an experienced team of specialists within world-class facilities, IDT provides a full-scale service for new drug development and scale-up, commercial active drug manufacture as well as a variety of oral and injectable finished drug dose forms.